Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with vascular PED due to AMD~* Male or female patients with the age \> 50 years~* Angiographic and via OCT ensured PED ≥ 200 µm in the eye for treatment~* Written informed consent~* Best corrected visual acuity (ETDRS-Visus): 24 - 73 letters within~Exclusion Criteria:~* Patients that do not fulfill the a. m. inclusion criteria~* Patients which have been treated with steroids or with verteporfin via photodynamic therapy or focal lasercoagulation treatment until 3 months before,~* Anti VEGF therapy until 1 month before screening~* Patients with other retinal vascular diseases including diabetic rethinopathia or retinal vein occlusion~* Other ocular operative procedurs 3 months before Screening~* Anamnesis of non controlled glaucoma~* Active or intraocular Inflammation or Inflammation of ocular adnexa~* Subfoveal fibrosis within study eye~* Larger surgical interventions 1 month before Screening~* Anamnesis of serious cardiovascular diseases or stroke 6 months before srceening~* Allergy of components of the study medication~* Patients which might be not compliant~* Patients participating at another clinical trial at the same time~* Pregnancy, breastfeeding, women in child-bearing years without using a safe contraception method~* Chronical alcohol- or drug abuse within the last year~* lack of capacity and/or knowledge of German language~* Neurologic disease i. e. multiple sclerosis

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).